Drug Interactions between Coartem and Dexone LA

DexAMETHasone may reduce the blood levels of artemether, which may make the medication less effective in treating malaria in some cases. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. Contact your doctor if your symptoms worsen or your condition changes during treatment with these medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized by the isoenzyme. Loss of antimalarial efficacy may occur. In six HIV-1 and tuberculosis coinfected adults without malaria, administration of artemether-lumefantrine (six-dose regimen over 3 days) with the potent CYP450 3A4 inducer rifampin (600 mg orally daily) decreased the systemic exposure (AUC) to artemether, dihydroartemisinin (the active metabolite of artemether) and lumefantrine by 89%, 85% and 68%, respectively. No data are available for use with other, less potent inducers.

MANAGEMENT: Concomitant use of artemether-lumefantrine with CYP450 3A4 inducers should generally be avoided. Otherwise, caution is advised, and patients should be closely monitored for potentially diminished clinical response to artemether-lumefantrine therapy.